Pharmaceutical

BioVersys secures patent claims in China for BV100

BioVersys has announced the grant of key patent claims in China for the BV100 technology, the intravenous formulation of rifabutin.

Apr 2, 2025 - 06:00
BioVersys secures patent claims in China for BV100
BioVersys has announced the grant of key patent claims in China for the BV100 technology, the intravenous formulation of rifabutin.
Read the original article

Tags:

Previous Article

Platform trials: The challenges, benefits, and best practices to maximize result...

Next Article

FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Chol...

Jun 20, 2024

STAT+: HHS dispatches millions to next-generation Covid targets, including intranasal vaccine

STAT+: HHS dispatches millions to next-generation Covid...

Oct 14, 2023

Your morning biotech news roundup

Your morning biotech news roundup

Nov 7, 2023